- E-postelise.aasebo@uib.no
- BesøksadresseBB-byggetJonas Lies vei 91Rom6C131cA
- PostadressePostboks 78045020 Bergen
Bruker metoder innenfor massespektrometribasert kvantitativ proteomikk for å analysere leukemiceller fra pasienter med akutt myelogen leukemi (AML).
Prosjektet har som mål å finne prognostiske biomarkører som kan bidra til en mer tilpasset behandling av AML-pasienter.
Vitenskapelig artikkel
- (2017). Phosphoprotein DIGE profiles reflect blast differentiation, cytogenetic risk stratification, FLT3/NPM1 mutations and therapy response in acute myeloid leukaemia. Journal of Proteomics. 32-41.
- (2016). Systemic Analysis of Regulated Functional Networks. Methods in molecular biology. 287-310.
- (2016). Reliable FASP-based procedures for optimal quantitative proteomic and phosphoproteomic analysis on samples from acute myeloid leukemia patients. Biological Procedures Online. 1-10.
- (2015). Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis. Proteomics. 3361-3369.
- (2014). Performance of super-SILAC based quantitative proteomics for comparison of different acute myeloid leukemia (AML) cell lines. Proteomics. 1971-1976.
- (2014). Effects of blood contamination and the rostro-caudal gradient on the human cerebrospinal fluid proteome. PLOS ONE.
Vitenskapelig oversiktsartikkel/review
- (2019). An overview on G protein-coupled receptor-induced signal transduction in acute myeloid leukemia. Current Medicinal Chemistry. 5293-5316.
- (2018). Vacuolar ATPase as a possible therapeutic target in human acute myeloid leukemia. Expert Review of Hematology. 13-24.
- (2017). Therapeutic targeting of leukemic stem cells in acute myeloid leukemia - the biological background for possible strategies. Expert Opinion on Drug Discovery. 1053-1065.
- (2016). Selecting Sample Preparation Workflows for Mass Spectrometry-Based Proteomic and Phosphoproteomic Analysis of Patient Samples with Acute Myeloid Leukemia . Proteomes.
Kompetansefelt